Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

P9297

Sigma-Aldrich

Paromomycin sulfate salt

≥98% (TLC)

Synonyme(s) :

Aminosidine sulfate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C23H45N5O14 · xH2SO4
Numéro CAS:
Poids moléculaire :
615.63 (free base basis)
Numéro Beilstein :
5715182
Code UNSPSC :
51281663
ID de substance PubChem :
Nomenclature NACRES :
NA.85

Niveau de qualité

Pureté

≥98% (TLC)

Forme

powder

Spectre d'activité de l'antibiotique

Gram-negative bacteria
Gram-positive bacteria
parasites

Mode d’action

protein synthesis | interferes

Chaîne SMILES 

O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O[C@@]2([H])[C@H](O[C@@]3([H])[C@H](O)[C@H](O[C@]4([H])[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O4)[C@@H](CO)O3)[C@@H](O)[C@H](N)C[C@@H]2N)[C@@H]1N.C

InChI

1S/C23H45N5O14.CH4/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22;/h5-23,29-36H,1-4,24-28H2;1H4/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+;/m1./s1

Clé InChI

OYJABWUHUYVDMJ-UDXJMMFXSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Chemical structure: aminoglycoside

Application

Paromomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. It has in vitro and in vivo activity similar to neomycin. It is effective against Gram-negative bacteria, Gram-positive bacteria, some protozoan species, and limited antihelminth.
It is used to study bacterial protein synthesis at the level of 16S ribosomal RNA and 30S ribosome assembly. Paromomycin is used to study cytosine-cytosine (CC) mismatch-containing RNA molecules and is used to inhibit Cryptosporidium infection of a human enterocyte cell line.

Actions biochimiques/physiologiques

Paromomycin inhibits the initiation and elongation steps of protein synthesis by binding to 16S ribosomal RNA. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced and leads to cell death.

Conditionnement

1g,5g,25g

Autres remarques

Keep container tightly closed in a dry and well-ventilated place.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

R J Marshall et al.
The Journal of infectious diseases, 165(4), 772-774 (1992-04-01)
Cryptosporidium parvum is a protozoan parasite that causes severe enteritis in patients with AIDS for which there is no effective therapy. Paromomycin is a nonabsorbable aminoglycoside that is effective in the treatment of other intestinal protozoa. The ability of paromomycin
Tony J Tavares et al.
RNA (New York, N.Y.), 15(5), 911-922 (2009-03-31)
The structure of a cytosine-cytosine (CC) mismatch-containing RNA molecule derived from a hairpin structure in the thymidylate synthase mRNA that binds the aminoglycoside paromomycin with high affinity was determined using nuclear magnetic resonance (NMR) spectroscopy. The cytosines in the mismatch
Kazuki Saito et al.
Nucleic acids research, 43(9), 4591-4601 (2015-04-22)
In eukaryotes, the tRNA-mimicking polypeptide-chain release factor, eRF1, decodes stop codons on the ribosome in a complex with eRF3; this complex exhibits striking structural similarity to the tRNA-eEF1A-GTP complex. Although amino acid residues or motifs of eRF1 that are critical
Sarah Hendrickx et al.
PLoS neglected tropical diseases, 6(5), e1664-e1664 (2012-06-06)
Paromomycin (PMM) has recently been introduced for treatment of visceral leishmaniasis in India. Although no clinical resistance has yet been reported, proactive vigilance should be warranted. The present in vitro study compared the outcome and stability of experimental PMM-resistance induction
Joline Goossens et al.
Toxins, 4(4), 281-295 (2012-05-19)
It is recognized that mycotoxins can cause a variety of adverse health effects in animals, including altered gastrointestinal barrier function. It is the aim of the present study to determine whether mycotoxin-contaminated diets can alter the oral bioavailability of the

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique